-
1
-
-
85044679123
-
-
Parsippany, IMS Health
-
Aitken M, Blansett L, Mawrie R. Developments in cancer treatments, market dynamics, patient access and value. Parsippany: IMS Health; 2015.
-
(2015)
Developments in Cancer Treatments, Market Dynamics, Patient Access and Value
-
-
Aitken, M.1
Blansett, L.2
Mawrie, R.3
-
2
-
-
77954888008
-
A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden
-
PID: 19639352
-
Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ. 2010;11(2):195–203.
-
(2010)
Eur J Health Econ.
, vol.11
, Issue.2
, pp. 195-203
-
-
Persson, U.1
Willis, M.2
Odegaard, K.3
-
4
-
-
84944516806
-
reimbursement decisions for pharmaceuticals in sweden: the impact of disease severity and cost effectiveness
-
PID: 26093889
-
Svensson M, Nilsson FO, Arnberg K. reimbursement decisions for pharmaceuticals in sweden: the impact of disease severity and cost effectiveness. PharmacoEconomics. 2015;33(11):1229–36.
-
(2015)
PharmacoEconomics.
, vol.33
, Issue.11
, pp. 1229-1236
-
-
Svensson, M.1
Nilsson, F.O.2
Arnberg, K.3
-
5
-
-
85027379799
-
Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
-
PID: 28803265
-
Olofsson S, Gerdtham UG, Hultkrantz L, Persson U. Measuring the end-of-life premium in cancer using individual ex ante willingness to pay. Eur J Health Econ. 2017. https://doi.org/10.1007/s10198-017-0922-6.
-
(2017)
Eur J Health Econ
-
-
Olofsson, S.1
Gerdtham, U.G.2
Hultkrantz, L.3
Persson, U.4
-
6
-
-
85044631979
-
-
[cited 2017 March 3rd]; Available from
-
NT-Council. Recommendations by the NT-council [Rekommendationer av NT-rådet]. 2017 [cited 2017 March 3rd]; Available from: http://www.janusinfo.se/Nationellt-inforande-av-nya-lakemedel/Nationellt-inforande-av-nya-lakemedel/Rekommendationer1/.
-
(2017)
Recommendations by the NT-council [Rekommendationer av NT-rådet]
-
-
-
7
-
-
82555173357
-
-
National Guidelines for the Treatment of Breast, Prostate and Colorectal Cancers
-
Socialstyrelsen (The National Board of Health and Welfare). National Guidelines for the Treatment of Breast, Prostate and Colorectal Cancers; 2014.
-
(2014)
The National Board of Health and Welfare
-
-
-
8
-
-
85010254179
-
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
-
COI: 1:CAS:528:DC%2BC2sXktVKku7g%3D, PID: 27742709
-
Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016;128(24):2757–64.
-
(2016)
Blood.
, vol.128
, Issue.24
, pp. 2757-2764
-
-
Rajkumar, S.V.1
Harousseau, J.L.2
-
12
-
-
85044652088
-
-
[Underlag för beslut i landstingen; tilläggsanalys Kyprolis (karfilzomib)]. [Diarienummer: 2018/2016]
-
TLV. [Underlag för beslut i landstingen; tilläggsanalys Kyprolis (karfilzomib)]. [Diarienummer: 2018/2016]. 2017.
-
(2017)
-
-
-
14
-
-
84920846416
-
Do the current performance-based schemes in Italy really work? “Success fee”: a novel measure for cost-containment of drug expenditure
-
PID: 25595244
-
Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, et al. Do the current performance-based schemes in Italy really work? “Success fee”: a novel measure for cost-containment of drug expenditure. Value Health. 2015;18(1):131–6.
-
(2015)
Value Health.
, vol.18
, Issue.1
, pp. 131-136
-
-
Navarria, A.1
Drago, V.2
Gozzo, L.3
Longo, L.4
Mansueto, S.5
Pignataro, G.6
-
15
-
-
85027282325
-
Express Scripts leads indication-specific pricing with launch of OCV program
-
cited 2018 February 21st Available from
-
Kelly L. Express Scripts leads indication-specific pricing with launch of OCV program. Health Business Daily. 2016 [cited 2018 February 21st]; Available from: https://aishealth.com/archive/ndbn020516-02.
-
(2016)
Health Business Daily
-
-
Kelly, L.1
-
16
-
-
84867287477
-
Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs
-
PID: 22946789
-
Grima DT, Bernard LM, Dunn ES, McFarlane PA, Mendelssohn DC. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. PharmacoEconomics. 2012;30(11):981–9.
-
(2012)
PharmacoEconomics.
, vol.30
, Issue.11
, pp. 981-989
-
-
Grima, D.T.1
Bernard, L.M.2
Dunn, E.S.3
McFarlane, P.A.4
Mendelssohn, D.C.5
-
17
-
-
84877988784
-
Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al
-
PID: 23595557, (discussion 75–76)
-
van Baal P, Meltzer D, Brouwer W. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al. PharmacoEconomics. 2013;31(5):369–73 (discussion 75–76).
-
(2013)
PharmacoEconomics.
, vol.31
, Issue.5
, pp. 369-373
-
-
van Baal, P.1
Meltzer, D.2
Brouwer, W.3
-
18
-
-
84958125397
-
The end of the international reference pricing system?
-
PID: 26112982
-
Persson U, Jonsson B. The end of the international reference pricing system? Appl Health Econ Health Policy. 2016;14(1):1–8.
-
(2016)
Appl Health Econ Health Policy.
, vol.14
, Issue.1
, pp. 1-8
-
-
Persson, U.1
Jonsson, B.2
-
19
-
-
70350770990
-
The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer
-
PID: 19624617
-
Garrison LP Jr, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health. 2009;12(8):1118–23.
-
(2009)
Value Health.
, vol.12
, Issue.8
, pp. 1118-1123
-
-
Garrison, L.P.1
Veenstra, D.L.2
-
20
-
-
84908150068
-
Indication-specific pricing for cancer drugs
-
COI: 1:CAS:528:DC%2BC2cXitVSms7fN, PID: 25279433
-
Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312(16):1629–30.
-
(2014)
JAMA.
, vol.312
, Issue.16
, pp. 1629-1630
-
-
Bach, P.B.1
-
22
-
-
70350771916
-
Dynamic cost-effectiveness: A more efficient reimbursement criterion
-
Lundin D, Ramsberg J. Dynamic cost-effectiveness: a more efficient reimbursement criterion. In: Forum for Health Economics & Policy, vol 11, no 2. 2008.
-
(2008)
Forum for Health Economics & Policy
, vol.11
, Issue.2
-
-
Lundin, D.1
Ramsberg, J.2
-
23
-
-
85044622644
-
-
drugabacus.org. [cited 2017 March 3rd]; Available from
-
Bach PB. drugabacus.org. [cited 2017 March 3rd]; Available from: http://www.drugabacus.org/.
-
-
-
Bach, P.B.1
-
24
-
-
85062745192
-
Add-on therapy in breast cancer—probability of cost-effectiveness in economic analyses
-
Prząda-Machno P, Marzec M, Borowiack E, Nowotarska A, Jarosz J, Szczuka A, et al. Add-on therapy in breast cancer—probability of cost-effectiveness in economic analyses. Value Health. 2017;20(9):A445.
-
(2017)
Value Health.
, vol.20
, Issue.9
, pp. A445
-
-
Prząda-Machno, P.1
Marzec, M.2
Borowiack, E.3
Nowotarska, A.4
Jarosz, J.5
Szczuka, A.6
-
26
-
-
84855711056
-
Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement
-
PID: 22147861
-
Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood). 2011;30(12):2329–37.
-
(2011)
Health Aff (Millwood).
, vol.30
, Issue.12
, pp. 2329-2337
-
-
Neumann, P.J.1
Chambers, J.D.2
Simon, F.3
Meckley, L.M.4
-
27
-
-
77953704571
-
Multiple sclerosis risk sharing scheme: a costly failure
-
PID: 20522654
-
Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 2010;340:c1672.
-
(2010)
BMJ.
, vol.340
, pp. c1672
-
-
Raftery, J.1
-
28
-
-
84901661562
-
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers
-
PID: 24664994
-
Carlson JJ, Gries KS, Yeung K, Sullivan SD, Garrison LP Jr. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy. 2014;12(3):231–8.
-
(2014)
Appl Health Econ Health Policy.
, vol.12
, Issue.3
, pp. 231-238
-
-
Carlson, J.J.1
Gries, K.S.2
Yeung, K.3
Sullivan, S.D.4
Garrison, L.P.5
-
29
-
-
74549224065
-
The Nordic countries as a cohort for pharmacoepidemiological research
-
COI: 1:CAS:528:DC%2BC3cXhtlKgs74%3D, PID: 19961477
-
Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86–94.
-
(2010)
Basic Clin Pharmacol Toxicol.
, vol.106
, Issue.2
, pp. 86-94
-
-
Furu, K.1
Wettermark, B.2
Andersen, M.3
Martikainen, J.E.4
Almarsdottir, A.B.5
Sorensen, H.T.6
|